Literature DB >> 19603165

Proximal femoral replacements for metastatic bone disease: financial implications for sarcoma units.

Robert U Ashford1, Sammy A Hanna, Derek H Park, Rob C Pollock, John A Skinner, Timothy W R Briggs, Stephen R Cannon.   

Abstract

Metastatic pathological fractures of the proximal femur are increasingly treated by endoprosthetic proximal femoral replacement. We report the results and the costs incurred performing these procedures at our supra-regional sarcoma unit. Sixty-two patients underwent 63 proximal femoral replacements for metastatic bone disease over a seven-year period. Breast cancer was the most common primary pathology. One patient underwent a revision procedure for infection. Twenty-two patients suffered dislocations, most commonly those undergoing a conventional arthroplasty articulation. The estimated cost of a proximal femoral replacement is 18,002 pounds at our centre. Less than half of this is reimbursed under Payment by Results. Endoprosthetic replacement of the proximal femur is an effective treatment of metastases, but is poorly reimbursed under current funding arrangements.

Entities:  

Mesh:

Year:  2009        PMID: 19603165      PMCID: PMC2903164          DOI: 10.1007/s00264-009-0838-6

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  11 in total

1.  Prosthetic reconstruction of the femur for primary bone sarcoma.

Authors:  C H Gerrand; D Currie; P Grigoris; R Reid; D L Hamblen
Journal:  Int Orthop       Date:  1999       Impact factor: 3.075

2.  Treatment results of pathological fractures of the long bones: a retrospective analysis of 88 patients.

Authors:  Kambiz Sarahrudi; Katherina Hora; Thomas Heinz; Steven Millington; Vilmos Vécsei
Journal:  Int Orthop       Date:  2006-08-30       Impact factor: 3.075

3.  Endoprosthetic and allograft-prosthetic composite reconstruction of the proximal femur for bone neoplasms.

Authors:  Yasser Farid; Patrick P Lin; Valerae O Lewis; Alan W Yasko
Journal:  Clin Orthop Relat Res       Date:  2006-01       Impact factor: 4.176

Review 4.  Megaprostheses for the treatment of malignant bone tumours of the lower limbs.

Authors:  Christian Heisel; Stefan Kinkel; Ludger Bernd; Volker Ewerbeck
Journal:  Int Orthop       Date:  2006-09-12       Impact factor: 3.075

5.  The cost-effectiveness of limb salvage for bone tumours.

Authors:  R J Grimer; S R Carter; P B Pynsent
Journal:  J Bone Joint Surg Br       Date:  1997-07

6.  Lower limb salvage surgery: modular endoprosthesis in bone tumour treatment.

Authors:  D Orlic; M Smerdelj; R Kolundzic; M Bergovec
Journal:  Int Orthop       Date:  2006-08-08       Impact factor: 3.075

Review 7.  British Association of Surgical Oncology Guidelines. The management of metastatic bone disease in the United Kingdom. The Breast Specialty Group of the British Association of Surgical Oncology.

Authors: 
Journal:  Eur J Surg Oncol       Date:  1999-02       Impact factor: 4.424

8.  Endoprosthetic reconstruction for neoplasms of the proximal femur.

Authors:  Lawrence R Menendez; Elke R Ahlmann; Cyrus Kermani; Heather Gotha
Journal:  Clin Orthop Relat Res       Date:  2006-09       Impact factor: 4.176

9.  Functional outcome of endoprosthetic proximal femoral replacement.

Authors:  Christian M Ogilvie; Jay S Wunder; Peter C Ferguson; Anthony M Griffin; Robert S Bell
Journal:  Clin Orthop Relat Res       Date:  2004-09       Impact factor: 4.176

10.  Fracture healing in metastatic bone disease.

Authors:  B J Gainor; P Buchert
Journal:  Clin Orthop Relat Res       Date:  1983-09       Impact factor: 4.176

View more
  14 in total

1.  Reconstruction of the proximal femur with a modular resection prosthesis.

Authors:  Teresa Calabró; Rupert Van Rooyen; Ilaria Piraino; Elisa Pala; Giulia Trovarelli; Georgios N Panagopoulos; Panayiotis D Megaloikonomos; Andrea Angelini; Andreas F Mavrogenis; Pietro Ruggieri
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-04-04

2.  Megaprosthesis for Metastatic Bone Disease-A Comparative Analysis.

Authors:  Joachim Thorkildsen; Thale Asp Strøm; Nils Jørgen Strøm; Simen Sellevold; Ole-Jacob Norum
Journal:  Curr Oncol       Date:  2022-05-10       Impact factor: 3.109

Review 3.  Reducing the burden of bone metastases: current concepts and treatment options.

Authors:  Roger von Moos; Cora Sternberg; Jean-Jacques Body; Carsten Bokemeyer
Journal:  Support Care Cancer       Date:  2013-03-07       Impact factor: 3.603

4.  Is a Cephalomedullary Nail Durable Treatment for Patients With Metastatic Peritrochanteric Disease?

Authors:  David H Chafey; Valerae O Lewis; Robert L Satcher; Bryan S Moon; Patrick P Lin
Journal:  Clin Orthop Relat Res       Date:  2018-12       Impact factor: 4.176

5.  Metastatic bone disease: Have we improved after a decade of guidelines?

Authors:  P Harvie; D Whitwell
Journal:  Bone Joint Res       Date:  2013-06-01       Impact factor: 5.853

6.  Modular tumor endoprostheses in surgical palliation of long-bone metastases: a reduction in tumor burden and a durable reconstruction.

Authors:  Marcel-Philipp Henrichs; Juliane Krebs; Georg Gosheger; Arne Streitbuerger; Markus Nottrott; Tim Sauer; Steffen Hoell; Gurpal Singh; Jendrik Hardes
Journal:  World J Surg Oncol       Date:  2014-11-07       Impact factor: 2.754

7.  Results of the treatment of bone metastases with modular prosthetic replacement--analysis of 67 patients.

Authors:  Grzegorz Guzik
Journal:  J Orthop Surg Res       Date:  2016-02-05       Impact factor: 2.359

8.  Oncological and functional results after surgical treatment of bone metastases at the proximal femur.

Authors:  Grzegorz Guzik
Journal:  BMC Surg       Date:  2018-01-25       Impact factor: 2.102

9.  Hip Fracture Prevention in Osteoporotic Elderly and Cancer Patients: An On-Line French Survey Evaluating Current Needs.

Authors:  Laëtitia Rodrigues; François H Cornelis; Sylvie Chevret
Journal:  Medicina (Kaunas)       Date:  2020-08-07       Impact factor: 2.430

Review 10.  Multimodal Treatment of Bone Metastasis-A Surgical Perspective.

Authors:  Henry Soeharno; Lorenzo Povegliano; Peter F Choong
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-07       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.